$2.52
3.82% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Palisade Bio Inc Stock price

$2.52
-1.03 29.01% 1M
-3.86 60.50% 6M
-6.33 71.53% YTD
-5.43 68.31% 1Y
-2,014.98 99.88% 3Y
-4,164.44 99.94% 5Y
-3,299,397.48 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.10 3.82%
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Key metrics

Market capitalization $3.35m
Enterprise Value $-4.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.34
P/B ratio (TTM) P/B ratio 0.46
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.77m
Free Cash Flow (TTM) Free Cash Flow $-12.56m
Cash position $8.04m
EPS (TTM) EPS $-15.04
P/E forward negative
Short interest 3.27%
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Palisade Bio Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Palisade Bio Inc forecast:

Buy
100%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.05 6.05
1% 1%
-
- Research and Development Expense 8.71 8.71
16% 16%
-
-15 -15
11% 11%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
10% 10%
-
Net Profit -14 -14
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
4 days ago
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)
Neutral
GlobeNewsWire
16 days ago
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (G...
Neutral
GlobeNewsWire
about one month ago
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 9
Founded 2011
Website www.palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today